Treatment of Raynaud's phenomenon: new insights and developments.
Although certain broad principles of treatment apply to all patients with Raynaud's phenomenon, the exact approach will vary depending on the nature and severity of the underlying digital vascular problem. Advances in the understanding of the pathophysiology of Raynaud's phenomenon are directing new lines of therapy. This review considers general (nonpharmacologic) measures, the different types of drug therapy, and the role of surgery. Recent advances in the use of more conventional treatments, such as calcium channel blockers, are discussed and also newer agents that are currently being researched, for example, endothelin-1 receptor antagonists and nitric oxide donors. The necessity of prompt assessment and treatment of acute digital ischemia, which is a medical emergency, is highlighted.
Herrick
Ariane L
AL
University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford M6 8HD, UK. aherrick@fs1.ho.man.ac.uk
D000975:Antioxidants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D011928:Raynaud Disease / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000975:Antioxidants; D014665:Vasodilator Agents